SI-Bone (NASDAQ:SIBN) & T2 Biosystems (NASDAQ:TTOO) Head-To-Head Review

T2 Biosystems (NASDAQ:TTOO) and SI-Bone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.


This table compares T2 Biosystems and SI-Bone’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
T2 Biosystems -545.93% N/A -128.49%
SI-Bone -68.27% -51.27% -32.29%

Analyst Recommendations

This is a summary of recent ratings and price targets for T2 Biosystems and SI-Bone, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
T2 Biosystems 0 2 3 0 2.60
SI-Bone 0 0 6 0 3.00

T2 Biosystems currently has a consensus target price of $3.50, suggesting a potential upside of 173.44%. SI-Bone has a consensus target price of $24.50, suggesting a potential upside of 3.07%. Given T2 Biosystems’ higher probable upside, equities analysts clearly believe T2 Biosystems is more favorable than SI-Bone.

Risk and Volatility

T2 Biosystems has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, SI-Bone has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Valuation and Earnings

This table compares T2 Biosystems and SI-Bone’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
T2 Biosystems $8.34 million 22.71 -$59.01 million ($1.30) -0.98
SI-Bone $67.30 million 10.11 -$38.40 million ($1.55) -15.34

SI-Bone has higher revenue and earnings than T2 Biosystems. SI-Bone is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.1% of T2 Biosystems shares are held by institutional investors. Comparatively, 66.7% of SI-Bone shares are held by institutional investors. 8.2% of T2 Biosystems shares are held by insiders. Comparatively, 15.5% of SI-Bone shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


SI-Bone beats T2 Biosystems on 9 of the 14 factors compared between the two stocks.

T2 Biosystems Company Profile

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

SI-Bone Company Profile

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with's FREE daily email newsletter.